Alzamend Neuro, Inc.
ALZN
$0.67
-$0.04-5.63%
NASDAQ
01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
---|---|---|---|---|---|
Net Income | 65.92% | 61.07% | 51.89% | 33.14% | 19.69% |
Total Depreciation and Amortization | 17.05% | 41.11% | 77.62% | 120.87% | 104.72% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -75.45% | -83.61% | -78.04% | -73.31% | -68.57% |
Change in Net Operating Assets | -281.02% | -169.73% | -75.16% | -71.46% | -32.25% |
Cash from Operations | 19.52% | 10.61% | 37.76% | 7.32% | -10.04% |
Capital Expenditure | 38.86% | 38.86% | 38.86% | -- | -38.22% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | 38.86% | 38.86% | 38.86% | -- | -38.22% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 117.01% | 13,061.75% | 626,150.00% | 626,150.00% | -75.44% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | 599.01% | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 390.97% | 64,912.02% | 2,807,950.00% | 1,826,150.00% | -45.90% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 143.36% | 143.34% | 94.90% | 46.60% | -60.67% |